Find your next paid study

~$75 – $3,000

Actual pay is set by the research site.

GenmabNCT07288177

NSCLC Stage IVALK Fusion Protein Expression

Pilot Study of a Prophylactic Cancer Peptide Vaccine in Advanced ALK+ NSCLC

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients c…

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05950139

~$150 – $3,000

Actual pay is set by the research site.

NSCLC AdenocarcinomaGastroesophageal Cancer (GC)Gastric Adenocarcinoma+10 more

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents …

IDEAYA BiosciencesNCT07277413

Actual pay is set by the research site.

Solid Tumor, AdultColorectal CancerNSCLC+17 more

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A02 Expression

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic …

Actual pay is set by the research site.

Advanced Solid TumorOvarian CancerEndometrial Cancer+1 more

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

TORL Biotherapeutics, LLCNCT05103683

Actual pay is set by the research site.

Phase 2

A Phase II Randomized Open-Label Trial of Levetiracetam for Prevention of Seizures in Patients With Brain Metastases in Primary Motor Cortex

This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-sei…

SeizuresPrimary Motor CortexBrain Metastases From Non-small Cell Lung Cancer (NSCLC)+2 more

Ayal A. Aizer, MDNCT07130786

~$75 – $3,000

Actual pay is set by the research site.

Solid Tumor, AdultMesotheliomaNSCLC

Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or i…

Vivace Therapeutics, IncNCT04665206

Actual pay is set by the research site.

ALK-positive NSCLCALK-Positive Lung CancerALK-positive Non-small Cell Lung Cancer

A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung …

TRIANA Biomedicines, Inc.NCT07491497

Actual pay is set by the research site.

Phase 2

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid …

Solid TumorsAdvanced CancerRenal Cancer+15 more

Apollomics Inc.NCT03175224

~$75 – $2,800

Actual pay is set by the research site.

Phase 3

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Can…

Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers SquibbNCT07361497

~$50 – $2,250

Actual pay is set by the research site.

Non-small Cell Lung Cancer (NSCLC)Cachexia

AN INTERVENTIONAL, PHASE 1B, DOUBLE-BLIND, RANDOMIZED, SPONSOR-OPEN, 2-ARM STUDY TO INVESTIGATE THE EFFECT OF PONSEGROMAB ON SKELETAL MUSCLE MASS AND PHYSICAL FUNCTION IN ADULT PARTICIPANTS WITH NON-SMALL CELL LUNG CANCER ASSOCIATED CACHEXIA

Study to investigate the effect of ponsegromab on skeletal muscle mass and physical function in adult participants with non-small cell lung cancer associated c…

~$150 – $4,500

Actual pay is set by the research site.

PfizerNCT07663630

Solid TumorSmall Cell Lung Cancer (SCLC)High Grade Neuroendocrine Cancer+9 more

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select…